Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sufentanyl in TAP Block After Cesarean Delivery
NCT01516268Phase 4
Key facts
- Status
- Completed
- Start
- Jan 2012
- Primary completion
- Feb 2013
- Countries
- 1
- Sponsor
- Tehran University of Medical Sciences
- Modality
- Orthosteric Ligands
- Drugs
- sufentanil
- Conditions
- pain
01
Overview
Phase 4, randomised trial of sufentanil in pain (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Narcotic Dosage. Started Jan 2012; status: completed.
02
Design
2 arms- Study design
- Randomized
Sufentanyl group
1cc sufentanyl added to 20 cc bupivacain in TAP block
Control group
1cc normal saline added to 20cc bupivacain in TAP block
03
Who it enrols
Women aged 18-40, ASA class 1 or 2, scheduled for elective cesarean section, excluding those with major organ failure, coagulopathy, morbid obesity, smoking, or history of post-operative nausea and vomiting.
04
Endpoints
Primary
Narcotic Dosage
Secondary
Pain Score
Beyond the preview
Go deeper on NCT01516268.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01516268.